Tempus Reports First Quarter 2026 Results
Tempus AI, Inc. reported a revenue of $348.1 million for Q1 2026, marking a 36.1% increase compared to the previous year. Diagnostics revenue reached $261.1 million with a growth of 34.7%, driven by a 28% increase in Oncology volume. The number of MRD tests conducted was around 6,500, showing a remarkable growth of about 500% year-over-year. Data and Applications revenue accounted for $87.0 million during this period.
CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. Revenue of $348.1 million, up 36.1% year-over-year Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% MRD volume was ~6,500 tests in Q1 2026, up ~500% year-over-year Data and Applications revenue of $87.0